Does the media favor ELAN or ARQT?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 31 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.81 beat Arcutis Biotherapeutics' score of 0.76 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ARQT or AXSM?

In the previous week, Arcutis Biotherapeutics had 23 more articles in the media than Axsome Therapeutics. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 14 mentions for Axsome Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.76 beat Axsome Therapeutics' score of 0.59 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABVX or ARQT?

In the previous week, Arcutis Biotherapeutics had 36 more articles in the media than Abivax. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.23 beat Arcutis Biotherapeutics' score of 0.76 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer KRYS or ARQT?

In the previous week, Arcutis Biotherapeutics had 14 more articles in the media than Krystal Biotech. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 23 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.90 beat Arcutis Biotherapeutics' score of 0.76 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 5 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Arcutis Biotherapeutics (ARQT) Competitors

$25.29 -1.14 (-4.31%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$25.34 +0.05 (+0.20%)

As of 08/7/2026 07:34 PM Eastern

Compare

ARQT vs. ELAN, ARWR, AXSM, ABVX, and KRYS

Should you buy Arcutis Biotherapeutics stock or one of its competitors? MarketBeat compares Arcutis Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcutis Biotherapeutics include Elanco Animal Health (ELAN), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Abivax (ABVX), and Krystal Biotech (KRYS).

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Elanco Animal Health's net margin of -3.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Elanco Animal Health presently has a consensus target price of $29.09, indicating a potential upside of 31.88%. Arcutis Biotherapeutics has a consensus target price of $35.57, indicating a potential upside of 40.65%. Given Arcutis Biotherapeutics' higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arcutis Biotherapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.20	-$232M	-$0.41	N/A
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Elanco Animal Health. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 31 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.81 beat Arcutis Biotherapeutics' score of 0.76 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arcutis Biotherapeutics beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arcutis Biotherapeutics' return on equity of 15.05% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.89	-$1.63M	-$2.25	N/A
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43

In the previous week, Arcutis Biotherapeutics had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 28 mentions for Arrowhead Pharmaceuticals. Arcutis Biotherapeutics' average media sentiment score of 0.76 beat Arrowhead Pharmaceuticals' score of -0.11 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals currently has a consensus target price of $97.33, indicating a potential upside of 11.05%. Arcutis Biotherapeutics has a consensus target price of $35.57, indicating a potential upside of 40.65%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Arcutis Biotherapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43
Axsome Therapeutics	$708.24M	15.46	-$183.17M	-$3.73	N/A

Arcutis Biotherapeutics has a net margin of 6.15% compared to Axsome Therapeutics' net margin of -26.59%. Arcutis Biotherapeutics' return on equity of 15.05% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 40.65%. Axsome Therapeutics has a consensus price target of $265.55, indicating a potential upside of 24.82%. Given Arcutis Biotherapeutics' higher possible upside, research analysts clearly believe Arcutis Biotherapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.91

81.5% of Axsome Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arcutis Biotherapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 23 more articles in the media than Axsome Therapeutics. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 14 mentions for Axsome Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.76 beat Axsome Therapeutics' score of 0.59 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Axsome Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Abivax's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Arcutis Biotherapeutics has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43

Abivax has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Abivax currently has a consensus price target of $156.50, suggesting a potential upside of 19.53%. Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 40.65%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

47.9% of Abivax shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Arcutis Biotherapeutics had 36 more articles in the media than Abivax. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 1 mentions for Abivax. Abivax's average media sentiment score of 1.23 beat Arcutis Biotherapeutics' score of 0.76 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Arcutis Biotherapeutics had 14 more articles in the media than Krystal Biotech. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 23 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.90 beat Arcutis Biotherapeutics' score of 0.76 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	5 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Krystal Biotech has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Krystal Biotech has higher earnings, but lower revenue than Arcutis Biotherapeutics. Krystal Biotech is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$440.48M	21.94	$204.83M	$7.98	40.91
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43

Krystal Biotech has a net margin of 54.82% compared to Arcutis Biotherapeutics' net margin of 6.15%. Krystal Biotech's return on equity of 19.34% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Krystal Biotech currently has a consensus target price of $361.56, suggesting a potential upside of 10.75%. Arcutis Biotherapeutics has a consensus target price of $35.57, suggesting a potential upside of 40.65%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.92
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

86.3% of Krystal Biotech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Krystal Biotech beats Arcutis Biotherapeutics on 12 of the 17 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.16B	$11.85B	$7.01B	$13.00B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	120.43	790.97	271.11	25.19
Price / Sales	6.82	743.77	595.59	79.93
Price / Cash	N/A	71.16	71.81	50.72
Price / Book	14.37	10.75	13.25	6.22
Net Income	-$16.14M	$2.78B	$3.45B	$342.66M
7 Day Performance	-5.85%	3.36%	4.67%	4.41%
1 Month Performance	-12.13%	-0.81%	-1.28%	-1.10%
1 Year Performance	71.23%	192.86%	77.33%	23.99%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	4.2533 of 5 stars	$25.29 -4.3%	$35.57 +40.7%	+71.2%	$3.16B	$463.98M	120.43	150	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
ELAN Elanco Animal Health	4.3355 of 5 stars	$26.35 +3.3%	$28.73 +9.0%	+32.8%	$12.75B	$4.72B	N/A	9,400	News Coverage Earnings Report Analyst Forecast
ARWR Arrowhead Pharmaceuticals	1.6502 of 5 stars	$86.22 +0.5%	$95.08 +10.3%	+433.8%	$12.08B	$829.45M	N/A	400	Trending News Earnings Report Analyst Forecast Analyst Revision Gap Up
AXSM Axsome Therapeutics	3.653 of 5 stars	$227.42 -2.9%	$261.48 +15.0%	+103.0%	$12.05B	$638.50M	N/A	380	Upcoming Earnings Insider Trade
ABVX Abivax	3.2279 of 5 stars	$118.84 -4.3%	$156.50 +31.7%	+86.7%	$10.84B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, ARWR, AXSM, ABVX, and KRYS

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Abivax?

Summary

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, ARWR, AXSM, ABVX, and KRYS

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Is ELAN or ARQT more profitable?

Which has more risk and volatility, ELAN or ARQT?

Do analysts rate ELAN or ARQT?

Which has better earnings and valuation, ELAN or ARQT?

Does the media favor ELAN or ARQT?

Do institutionals and insiders believe in ELAN or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Is ARWR or ARQT more profitable?

Do institutionals and insiders hold more shares of ARWR or ARQT?

Which has stronger valuation & earnings, ARWR or ARQT?

Does the media refer more to ARWR or ARQT?

Do analysts rate ARWR or ARQT?

Which has more volatility and risk, ARWR or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Which has stronger earnings & valuation, ARQT or AXSM?

Is ARQT or AXSM more profitable?

Do analysts recommend ARQT or AXSM?

Do institutionals & insiders hold more shares of ARQT or AXSM?

Which has more volatility and risk, ARQT or AXSM?

Does the media refer more to ARQT or AXSM?

Summary

How does Arcutis Biotherapeutics compare to Abivax?

Is ABVX or ARQT more profitable?

Which has better valuation and earnings, ABVX or ARQT?

Which has more risk & volatility, ABVX or ARQT?

Do analysts recommend ABVX or ARQT?

Do institutionals & insiders hold more shares of ABVX or ARQT?

Does the media refer more to ABVX or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Krystal Biotech?

Does the media prefer KRYS or ARQT?

Which has more risk and volatility, KRYS or ARQT?

Which has preferable valuation and earnings, KRYS or ARQT?

Is KRYS or ARQT more profitable?

Do analysts recommend KRYS or ARQT?

Do institutionals and insiders have more ownership in KRYS or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools